A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis. Ghani, H., Richards, E., Truong, T. M., Rao, B. K., & Zhang, A. Journal of drugs in dermatology: JDD, 22(10):1053–1057, October, 2023.
doi  abstract   bibtex   
Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10):     doi:10.36849/JDD.7540.
@article{ghani_review_2023,
	title = {A {Review} of the {Efficacy} of {Topical} {Statins} for {Treating} {Disseminated} {Superficial} {Actinic} {Porokeratosis}},
	volume = {22},
	issn = {1545-9616},
	doi = {10.36849/JDD.7540},
	abstract = {Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10\% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90\% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10):\  \  \ doi:10.36849/JDD.7540.},
	language = {eng},
	number = {10},
	journal = {Journal of drugs in dermatology: JDD},
	author = {Ghani, Hira and Richards, Elizabeth and Truong, Thu M. and Rao, Babar K. and Zhang, Alice},
	month = oct,
	year = {2023},
	pmid = {37801522},
	keywords = {Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Imiquimod, Photochemotherapy, Porokeratosis, Retinoids},
	pages = {1053--1057},
}

Downloads: 0